Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 8/2004

01-07-2004 | Current Opinion

Over-the-Counter Analgesics in Older Adults

A Call for Improved Labelling and Consumer Education

Authors: Dr Christianne L. Roumie, Marie R. Griffin

Published in: Drugs & Aging | Issue 8/2004

Login to get access

Abstract

The use of analgesics increases with age and on any given day 20–30% of older adults take an analgesic medication. Over-the-counter (OTC) analgesics are generally well tolerated and effective when taken for brief periods of time and at recommended dosages. However, their long-term use, use at inappropriately high doses, or use by persons with contraindications may result in adverse effects, including gastrointestinal haemorrhage, cardiovascular toxicity, renal toxicity and hepatotoxicity. Many OTC drugs are also available through a prescription, for a broader range of indications and for longer durations of use and wider dose ranges, under the assumption that healthcare providers will help patients make safe choices about analgesics. Safe and effective use of medications is one of the greatest challenges faced by healthcare providers in medicine. More than 60% of people cannot identify the active ingredient in their brand of pain reliever. Additionally, about 40% of Americans believe that OTC drugs are too weak to cause any real harm. As a result of a recent US FDA policy, the conversion of prescription to OTC medications will result in a 50% increase of OTC medications. To reduce the risks of potential adverse effects from OTC drug therapy in older adults, we propose that the use of analgesics will be enhanced through the use of patient and healthcare provider education, as well as improved labelling of OTC analgesics. Improved labelling of OTC analgesics may help consumers distinguish common analgesic ingredients in a wide variety of preparations and facilitate informed decisions concerning the use of OTC drugs.
Literature
1.
Gabriel SE, Fehring RA. Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States, 1986–1990. J Clin Epidemiol 1992; 45(9): 1041–4PubMedCrossRef
2.
Barat I, Andreasen F, Damsgaard EM. The consumption of drugs by 75-year-old individuals living in their own homes. Eur J Clin Pharmacol 2000; 56(6–7): 501–9PubMedCrossRef
3.
Stoehr GP, Ganguli M, Seaberg EC, et al. Over-the-counter medication use in an older rural community: the MoVIES Project. J Am Geriatr Soc 1997; 45(2): 158–65PubMed
4.
McManus P, Primrose JG, Henry DA, et al. Pattern of non-steroidal anti-inflammatory drug use in Australia 1990–1994: a report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Med J Aust 1996; 164(10): 589–92PubMed
5.
Thomas J, Straus WL, Bloom BS. Over-the-counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am J Gastroenterol 2002; 97(9): 2215–9PubMedCrossRef
6.
Sheen CL, Dillon JF, Bateman DN, et al. Paracetamol toxicity: epidemiology, prevention and costs to the health-care system. QJM 2002; 95(9): 609–19PubMedCrossRef
7.
Blenkinsopp A, Bradley C. Patients, society, and the increase in self medication. BMJ 1996; 312(7031): 629–32PubMedCrossRef
8.
Scheiman JM, Fendrick AM. NSAIDs without a prescription: over-the-counter access, under-counted risks. Am J Gastroenterol 2002; 97(9): 2159–61PubMedCrossRef
9.
Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289(9): 1107–16PubMedCrossRef
10.
Physicians Desk Reference. 57th ed. Montvale (NJ): Medical Economics Co., 2003
11.
Bradley JD, Katz BP, Brandt KD. Severity of knee pain does not predict a better response to an antiinflammatory dose of ibuprofen than to analgesic therapy in patients with osteoarthritis. J Rheumatol 2001; 28(5): 1073–6PubMed
12.
Pincus T, Griffin M. Gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs: new insights from observational studies and functional status questionnaires. Am J Med 1991; 91(3): 209–12PubMedCrossRef
13.
Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91(3): 213–22PubMedCrossRef
14.
Fries JF, Williams CA, Bloch DA. The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1991; 34(11): 1353–60PubMedCrossRef
15.
Dello Buono M, Urciuoli O, Marietta P, et al. Alternative medicine in a sample of 655 community-dwelling elderly. J Psychosom Res 2001; 50(3): 147–54CrossRef
16.
Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002; 27(6): 391–401PubMedCrossRef
17.
Motola G, Russo F, Mazzeo F, et al. Over-the-counter oral nonsteroidal anti-inflammatory drugs: a pharmacoepidemiologic study in southern Italy. Adv Ther 2001; 18(5): 216–22PubMedCrossRef
18.
Bradley CP, Taylor RJ, Blenkinsopp A. Primary care: opportunities and threats: developing prescribing in primary care. BMJ 1997; 314(7082): 744–7PubMedCrossRef
19.
Bradley C, Blenkinsopp A. Over the counter drugs: the future for self medication. BMJ 1996; 312(7034): 835–7PubMedCrossRef
20.
21.
Ehrlich GE. Guidelines for antiinflammatory drug research. J Clin Pharmacol 1977; 17(11–12): 697–703PubMed
22.
Advisory committees, OTC Drugs Advisory Committee: establishment, FDA: final rule. Fed Regist 1991; 56(185): 48103–4
23.
MacDonald TM, Beard K, Bruppacher R, et al. The safety of drugs for OTC use: what evidence is required for an NSAID switch? Pharmacoepidemiol Drug Saf 2002; 11(7): 577–84PubMedCrossRef
24.
Jain AK, Ryan JR, McMahon FG, et al. Analgesic efficacy of low-dose ibuprofen in dental extraction pain. Pharmacotherapy 1986; 6(6): 318–22PubMed
25.
Sunshine A, Olson NZ, Marrero I, et al. Onset and duration of analgesia for low-dose ketoprofen in the treatment of postoperative dental pain. J Clin Pharmacol 1998; 38(12): 1155–64PubMed
26.
Hyllested M, Jones S, Pedersen JL, et al. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br J Anaesth 2002; 88(2): 199–214PubMedCrossRef
27.
Eisenberg E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994; 12(12): 2756–65PubMed
28.
Sunshine A, Olson NZ. Analgesic efficacy of ketoprofen in postpartum, general surgery, and chronic cancer pain. J Clin Pharmacol 1988; 28(12 Suppl.): S47–54PubMed
29.
Shapiro SS. Treatment of dysmenorrhoea and premenstrual syndrome with non-steroidal anti-inflammatory drugs. Drugs 1988; 36(4): 475–90PubMedCrossRef
30.
Brass EP. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 2001; 345(11): 810–6PubMedCrossRef
31.
Craine Jr RB. Role of the pharmaceutical industry in health care cost containment. Am J Cardiol 1985; 56(5): 43–6CCrossRef
32.
Gurwitz JH. Suboptimal medication use in the elderly: the tip of the iceberg. JAMA 1994; 272(4): 316–7PubMedCrossRef
33.
Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287(3): 337–44PubMedCrossRef
34.
Curhan GC, Bullock AJ, Hankinson SE, et al. Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and aspirin in US women. Pharmacoepidemiol Drug Saf 2002; 11(8): 687–93PubMedCrossRef
35.
Cohen SM, Rousseau ME, Robinson EH. Therapeutic use of selected herbs. Holist Nurs Pract 2000; 14(3): 59–68PubMed
36.
Williamson AT, Fletcher PC, Dawson KA. Complementary and alternative medicine: use in an older population. J Gerontol Nurs 2003; 29(5): 20–8PubMed
37.
Ackman ML, Campbell JB, Buzak KA, et al. Use of nonprescription medications by patients with congestive heart failure. Ann Pharmacother 1999; 33(6): 674–9PubMedCrossRef
38.
39.
40.
41.
Leong AL, Euller-Ziegler L. Patient advocacy and arthritis: moving forward. Bull World Health Organ 2004; 82(2): 115–20PubMed
42.
43.
Haug MR, Musil CM, Warner CD, et al. Elderly persons’ interpretation of a bodily change as an illness symptom. J Aging Health 1997; 9(4): 529–52PubMedCrossRef
44.
Musil CM, Ahn S, Haug M, et al. Health problems and health actions among community-dwelling older adults: results of a health diary study. Appl Nurs Res 1998; 11(3): 138–47PubMedCrossRef
45.
Ford AB, Haug MR, Stange KC, et al. Sustained personal autonomy: a measure of successful aging. J Aging Health 2000; 12(4): 470–89PubMedCrossRef
46.
Ruoff G. Management of pain in patients with multiple health problems: a guide for the practicing physician. Am J Med 1998; 105(1B): 53–60SCrossRef
47.
Colley CA, Lucas LM. Polypharmacy: the cure becomes the disease. J Gen Intern Med 1993; 8(5): 278–83PubMedCrossRef
48.
Holden MD. Over-the-counter medications: do you know what your patients are taking? Postgrad Med 1992; 91(8): 191–4, 199-200PubMed
49.
Honig PK, Gillespie BK. Drug interactions between prescribed and over-the-counter medication. Drug Saf 1995; 13(5): 296–303PubMedCrossRef
50.
Honig PK, Gillespie BK. Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs. Clin Pharmacokinet 1998; 35(3): 167–71PubMedCrossRef
51.
Sleath B, Rubin RH, Campbell W, et al. Physician-patient communication about over-the-counter medications. Soc Sci Med 2001; 53(3): 357–69PubMedCrossRef
52.
Norris PT. Purchasing restricted medicines in New Zealand pharmacies: results from a “mystery shopper” study. Pharm World Sci 2002; 24(4): 149–53PubMedCrossRef
53.
Wallsten SM, Sullivan Jr RJ, Hanlon JT, et al. Medication taking behaviors in the high- and low-functioning elderly: MacArthur field studies of successful aging. Ann Pharmacother 1995; 29(4): 359–64PubMed
54.
Hersh EV, Moore PA, Ross GL. Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther 2000; 22(5): 500–48PubMedCrossRef
55.
Hernandez-Diaz S, Garcia-Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 110Suppl. 3A: 20–7SCrossRef
56.
Beyth RJ, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 1999; 14(3): 231–9PubMedCrossRef
57.
Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat 2000; 5(2): 137–42PubMed
58.
Bjorkman DJ. One hundred years of NSAID gastropathy: are coxibs the answer? Rev Gastroenterol Disord 2001; 1(3): 121–7PubMed
59.
Buffum M, Buffum JC. Nonsteroidal anti-inflammatory drugs in the elderly. Pain Manag Nurs 2000; 1(2): 40–50PubMedCrossRef
60.
Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996; 25(2): 373–96PubMedCrossRef
61.
Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996; 11(8): 461–9PubMedCrossRef
62.
Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141(6): 539–45PubMed
63.
Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 26Suppl. 56: 18–24
64.
Garcia Rodriguez LA, Walker AM, Perez Gutthann S, editor. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 1992; 3(4): 337–42
65.
Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343(8900): 769–72PubMedCrossRef
66.
Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312(7046): 1563–6PubMedCrossRef
67.
Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8(1): 18–24PubMedCrossRef
68.
Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum 1997; 26 (6 Suppl. 1): 16–20PubMedCrossRef
69.
Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158(1): 33–9PubMedCrossRef
70.
Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104(3A): 30–4SCrossRef
71.
Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114(4): 257–63PubMed
72.
Perez-Gutthann S, Garcia-Rodriguez LA, Duque-Oliart A, et al. Low-dose diclofenac, naproxen, and ibuprofen cohort study. Pharmacotherapy 1999; 19(7): 854–9PubMedCrossRef
73.
Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105(4): 1078–88PubMed
74.
Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int J Clin Pract Suppl 2003; 135: 43–9PubMed
75.
Strom BL, Schinnar R, Bilker WB, et al. Gastrointestinal tract bleeding associated with naproxen sodium vs ibuprofen. Arch Intern Med 1997; 157(22): 2626–31PubMedCrossRef
76.
Doyle G, Jayawardena S, Ashraf E, et al. Efficacy and tolerability of nonprescription ibuprofen versus celecoxib for dental pain. J Clin Pharmacol 2002; 42(8): 912–9PubMedCrossRef
77.
Doyle G, Furey S, Berlin R, et al. Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Aliment Pharmacol Ther 1999; 13(7): 897–906PubMedCrossRef
78.
Kellstein DE, Waksman JA, Furey SA, et al. The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis. J Clin Pharmacol 1999; 39(5): 520–32PubMed
79.
Cebollero-Santamaria F, Smith J, Gioe S, et al. Selective outpatient management of upper gastrointestinal bleeding in the elderly. Am J Gastroenterol 1999; 94(5): 1242–7PubMedCrossRef
80.
Lapane KL, Spooner JJ, Mucha L, et al. Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc 2001; 49(5): 577–84PubMedCrossRef
81.
Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995; 90(2): 206–10PubMed
82.
Peura DA, Lanza FL, Gostout CJ, et al. The American College of Gastroenterology Bleeding Registry: preliminary findings. Am J Gastroenterol 1997; 92(6): 924–8PubMed
83.
Hirschowitz BI, Lanas A. NSAID association with gastrointestinal bleeding and peptic ulcer. Agents Actions Suppl 1991; 35: 93–101PubMed
84.
Guess HA, West R, Strand LM, et al. Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. J Clin Epidemiol 1988; 41(1): 35–45PubMedCrossRef
85.
Maliekal J, Elboim CM. Gastrointestinal complications associated with intramuscular ketorolac tromethamine therapy in the elderly. Ann Pharmacother 1995; 29(7–8): 698–701PubMed
86.
Silverstein FE, Gilbert DA, Tedesco FJ, et al. The national ASGE survey on upper gastrointestinal bleeding (II): clinical prognostic factors. Gastrointest Endosc 1981; 27(2): 80–93PubMedCrossRef
87.
Dennis VC, Thomas BK, Hanlon JE. Potentiation of oral anticoagulation and hemarthrosis associated with nabumetone. Pharmacotherapy 2000; 20(2): 234–9PubMedCrossRef
88.
Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153(14): 1665–70PubMedCrossRef
89.
Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians’ fears often unfounded. Arch Intern Med 2003; 163(13): 1580–6PubMedCrossRef
90.
Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93(11): 2037–46PubMedCrossRef
91.
Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39(5): 723–31
92.
Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Questionable prescribing for elderly patients in Quebec. CMAJ 1994; 150(11): 1801–9PubMed
93.
Tamblyn R, Berkson L, Dauphinee WD, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997; 127(6): 429–38PubMed
94.
Johnson AG, Nguyen TV, Owe-Young R, et al. Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. J Hum Hypertens 1996; 10(4): 257–61PubMed
95.
Johnson AG. NSAIDs and increased blood pressure: what is the clinical significance? Drug Saf 1997; 17(5): 277–89PubMedCrossRef
96.
Johnson AG. NSAIDs and blood pressure: clinical importance for older patients. Drugs Aging 1998; 12(1): 17–27PubMedCrossRef
97.
Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure: a meta-analysis. Ann Intern Med 1994; 121(4): 289–300PubMed
98.
Feenstra J, Heerdink ER, Grobbee DE, et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med 2002; 162(3): 265–70PubMedCrossRef
99.
Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under-recognized public health problem. Arch Intern Med 2000; 160(6): 777–84PubMedCrossRef
100.
Merlo J, Broms K, Lindblad U, et al. Association of outpatient utilisation of non-steroidal anti-inflammatory drugs and hospitalised heart failure in the entire Swedish population. Eur J Clin Pharmacol 2001; 57(1): 71–5PubMedCrossRef
101.
Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003; 14(2): 240–6PubMed
102.
American Heart Association. 2002 heart and stroke statistical update. Dallas (TX): American Heart Association, 2001
103.
Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345(18): 1291–7PubMedCrossRef
104.
Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther 1998; 20(3): 376–87PubMedCrossRef
105.
Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90(5A): 42–7SCrossRef
106.
Houston MC, Weir M, Gray J, et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155(10): 1049–54PubMedCrossRef
107.
Gurwitz JH, Avorn J, Bohn RL, et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994; 272(10): 781–6PubMedCrossRef
108.
Johnson AG, Simons LA, Simons J, et al. Non-steroidal antiinflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. Br J Clin Pharmacol 1993; 35(5): 455–9PubMedCrossRef
109.
Chrischilles EA, Wallace RB. Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. J Gerontol 1993; 48(3): M91–6PubMedCrossRef
110.
Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153(4): 477–84PubMedCrossRef
111.
Oates JA, FitzGerald GA, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med 1988; 319(11): 689–98PubMedCrossRef
112.
Oates JA, FitzGerald GA, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med 1988; 319(12): 761–7PubMedCrossRef
113.
Jensen BL, Mann B, Skott O, et al. Differential regulation of renal prostaglandin receptor mRNAs by dietary salt intake in the rat. Kidney Int 1999; 56(2): 528–37PubMedCrossRef
114.
Breyer MD, Jacobson HR, Hebert RL. Cellular mechanisms of prostaglandin E2 and vasopressin interactions in the collecting duct. Kidney Int 1990; 38(4): 618–24PubMedCrossRef
115.
Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32(1): 1–12PubMedCrossRef
116.
Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31(7): 588–98PubMed
117.
Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160(10): 1465–70PubMedCrossRef
118.
Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331(25): 1675–9PubMedCrossRef
119.
Sandier DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115(3): 165–72
120.
Field TS, Gurwitz JH, Glynn RJ, et al. The renal effects of nonsteroidal anti-inflammatory drugs in older people: findings from the established populations for epidemiologic studies of the elderly. J Am Geriatr Soc 1999; 47(5): 507–11PubMed
121.
Gurwitz JH, Avorn J, Ross-Degnan D, et al. Nonsteroidal antiinflammatory drug-associated azotemia in the very old. JAMA 1990; 264(4): 471–5PubMedCrossRef
122.
Griffin MR, Yared A, Ray WA. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151(5): 488–96PubMedCrossRef
123.
Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, et al. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996; 156(21): 2433–9PubMedCrossRef
124.
Evans JM, McGregor E, McMahon AD, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM 1995; 88(8): 551–7PubMed
125.
Henry D, Page J, Whyte I, et al. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects: results of a case-control study. Br J Clin Pharmacol 1997; 44(1): 85–90PubMedCrossRef
126.
127.
Eastwood HD. Causes of jaundice in the elderly: a survey of diagnosis and investigation. Gerontol Clin (Basel) 1971; 13(1): 69–81CrossRef
128.
Cham E, Hall L, Ernst AA, et al. Awareness and use of over-the-counter pain medications: a survey of emergency department patients. South Med J 2002; 95(5): 529–35PubMed
129.
Chen L, Schneider S, Wax P. Knowledge about acetaminophen toxicity among emergency department visitors. Vet Hum Toxicol 2002; 44(6): 370–3PubMed
130.
Jowett NI. Limitation of over the counter sales of paracetamol: restriction of 16g will not prevent overdose and is unhelpful for patients with chronic disease [letter]. BMJ 1998; 317(7173): 1657PubMedCrossRef
131.
132.
Rabbani F, Cheema FH, Talati N, et al. Behind the counter: pharmacies and dispensing patterns of pharmacy attendants in Karachi. J Pak Med Assoc 2001; 51(4): 149–53PubMed
133.
Hawton K. United Kingdom legislation on pack sizes of analgesics: background, rationale, and effects on suicide and deliberate self-harm. Suicide Life Threat Behav 2002; 32(3): 223–9PubMedCrossRef
134.
Hawton K, Townsend E, Deeks J, et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ 2001; 322(7296): 1203–7PubMedCrossRef
135.
Pitkala KH, Strandberg TE, Tilvis RS. Management of nonmalignant pain in home-dwelling older people: a population-based survey. J Am Geriatr Soc 2002; 50(11): 1861–5PubMedCrossRef
136.
Gloth III FM. Concerns with chronic analgesic therapy in elderly patients. Am J Med 1996; 101(1A): 19–24S
137.
Gloth III FM. Geriatric pain: factors that limit pain relief and increase complications. Geriatrics 2000; 55(10): 46–8, 51-4PubMed
138.
Brandt KD, Bradley JD. Should the initial drug used to treat osteoarthritis pain be a nonsteroidal antiinflammatory drug? J Rheumatol 2001; 28(3): 467–73PubMed
139.
Griffin MR, Brandt KD, Liang MH, et al. Practical management of osteoarthritis: integration of pharmacologic and nonpharmacologic measures. Arch Fam Med 1995; 4(12): 1049–55PubMedCrossRef
140.
Puett DW, Griffin MR. Published trials of nonmedicinal and noninvasive therapies for hip and knee osteoarthritis. Ann Intern Med 1994; 121(2): 133–40PubMed
141.
Scudds RJ, Robertson JM. Pain factors associated with physical disability in a sample of community-dwelling senior citizens. J Gerontol A Biol Sci Med Sci 2000; 55(7): M393–9PubMedCrossRef
142.
Won A, Lapane K, Gambassi G, et al. Correlates and management of nonmalignant pain in the nursing home, SAGE Study Group: systematic assessment of geriatric drug use via epidemiology. J Am Geriatr Soc 1999; 47(8): 936–42PubMed
143.
Scudds RJ, Ostbye T. Pain and pain-related interference with function in older Canadians: the Canadian Study of Health and Aging. Disabil Rehabil 2001; 23(15): 654–64PubMedCrossRef
144.
Leveille SG, Ling S, Hochberg MC, et al. Widespread musculoskeletal pain and the progression of disability in older disabled women. Ann Intern Med 2001; 135(12): 1038–46PubMed
145.
Scudds RJ, McD Robertson J. Empirical evidence of the association between the presence of musculoskeletal pain and physical disability in community-dwelling senior citizens. Pain 1998; 75(2–3): 229–35PubMedCrossRef
146.
Espino DV, Lichtenstein MJ, Hazuda HP, et al. Correlates of prescription and over-the-counter medication usage among older Mexican Americans: the Hispanic EPESE study (Established Population for the Epidemiologic Study of the Elderly). J Am Geriatr Soc 1998; 46(10): 1228–34PubMed
147.
Vogel RJ, Ramachandran S, Zachry WM. A 3-stage model for assessing the probable economic effects of direct-to-consumer advertising of Pharmaceuticals. Clin Ther 2003; 25(1): 309–29PubMedCrossRef
148.
Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 1995; 274(1): 35–43PubMedCrossRef
149.
Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324(6): 377–84PubMedCrossRef
150.
Leape LL. Institute of Medicine medical error figures are not exaggerated. JAMA 2000; 284(1): 95–7PubMedCrossRef
151.
Fischer LR, Scott LM, Boonstra DM, et al. Pharmaceutical care for patients with chronic conditions. J Am Pharm Assoc (Wash) 2000; 40(2): 174–80
152.
Powell MJ, Knapp PB, Raynor DK. Testing the understanding of current and alternative warnings for paracetamol. Health Services Research and Pharmacy Practice Conference; 2001 Apr 19–20; Nottingham
153.
Gazmararian JA, Baker DW, Williams MV, et al. Health literacy among Medicare enrollees in a managed care organization. JAMA 1999; 281(6): 545–51PubMedCrossRef
154.
Brown H, Prisuta R, Jacobs B, et al. Literacy of older adults in America. Washington, DC: National Center for Education Statistics; 1996 Jan 23. Report no. NCES 97576
155.
Mrvos R, Dean BS, Krenzelok EP. Illiteracy: a contributing factor to poisoning. Vet Hum Toxicol 1993; 35(5): 466–8PubMed
156.
Olson RM, Blank D, Cardinal E, et al. Understanding medication-related needs of low-literacy patients. J Am Pharm Assoc (Wash) 1996; NS36(7): 424–9
157.
Mansoor LE, Dowse R. Effect of pictograms on readability of patient information materials. Ann Pharmacother 2003; 37(7–8): 1003–9PubMedCrossRef
158.
Ziegler DK, Mosier MC, Buenaver M, et al. How much information about adverse effects of medication do patients want from physicians? Arch Intern Med 2001; 161(5): 706–13PubMedCrossRef
159.
Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother 2001; 35(5): 539–45PubMedCrossRef
160.
Woloshin KK, Ruffin IV MT, Gorenflo DW. Patients’ interpretation of qualitative probability statements. Arch Fam Med 1994; 3(11): 961–6PubMedCrossRef
161.
Ngoh LN, Shepherd MD. Design, development, and evaluation of visual aids for communicating prescription drug instructions to nonliterate patients in rural Cameroon. Patient Educ Couns 1997; 31(3): 245–61PubMedCrossRef
162.
Ganguli M, Seaberg E, Belle S, et al. Cognitive impairment and the use of health services in an elderly rural population: the MoVIES project (Monongahela Valley Independent Elders Survey). J Am Geriatr Soc 1993; 41(10): 1065–70PubMed
163.
Alander SW, Dowd MD, Bratton SL, et al. Pediatric acetaminophen overdose: risk factors associated with hepatocellular injury. Arch Pediatr Adolesc Med 2000; 154(4): 346–50PubMed
164.
Barrett TW, Norton VC. Parental knowledge of different acetaminophen concentrations for infants and children. Acad Emerg Med 2000; 7(6): 718–21PubMedCrossRef
165.
Klein-Schwartz W, Oderda GM. Poisoning in the elderly: epidemiological, clinical and management considerations. Drugs Aging 1991; 1(1): 67–89PubMedCrossRef
166.
Dodd MD, Graham CA. Unintentional overdose of analgesia secondary to acute dental pain. Br Dent J 2002; 193(4): 211–2PubMedCrossRef
167.
Kisely SR, Lawrence D, Preston NJ. The effect of recalling paracetamol on hospital admissions for poisoning in Western Australia. Med J Aust 2003; 178(2): 72–4PubMed
168.
Caravati EM. Unintentional acetaminophen ingestion in children and the potential for hepatotoxicity. J Toxicol Clin Toxicol 2000; 38(3): 291–6PubMedCrossRef
169.
Chui PT. Anesthesia in a patient with undiagnosed salicylate poisoning presenting as intraabdominal sepsis. J Clin Anesth 1999; 11(3): 251–3PubMedCrossRef
170.
Berry DC, Raynor DK, Knapp P, et al. Patients’ understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf 2003; 26(1): 1–11PubMedCrossRef
171.
Berry DC, Raynor DK, Knapp P, et al. Over the counter medicines and the need for immediate action: a further evaluation of European Commission recommended wordings for communicating risk. Patient Educ Couns. In Press
Metadata
Title
Over-the-Counter Analgesics in Older Adults
A Call for Improved Labelling and Consumer Education
Authors
Dr Christianne L. Roumie
Marie R. Griffin
Publication date
01-07-2004
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2004
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200421080-00001
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits